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ABSTRACT
Background: Hyperglycaemia is associated with poor
outcomes from exacerbations of chronic obstructive
pulmonary disease (COPD). Glycaemic control could
improve outcomes by reducing infection, inﬂammation
and myopathy. Most patients with COPD are managed
on the acute medical unit (AMU) outside intensive care
(ICU).
Objective: To determine the feasibility, safety and
efﬁcacy of tight glycaemic control in patients on an
AMU.
Design: Prospective, non-randomised, phase II,
single-arm study of tight glycaemic control in COPD
patients with acute exacerbations and hyperglycaemia
admitted to the AMU. Participants received
intravenous, then subcutaneous, insulin to control
blood glucose to 4.4e6.5 mmol/l. Tight glycaemic
control was evaluated: feasibility, protocol adherence;
acceptability, patient questionnaire; safety, frequency
of hypoglycaemia (capillary blood glucose (CBG)
<2.2 mmol/l and 2.2e3.3 mmol/l); efﬁcacy, median
CBG, fasting CBG, proportion of measurements/time in
target range, glycaemic variability. Results were
compared with 25 published ICU studies.
Results: 20 patients (10 females, age 7169 years;
forced expiratory volume in 1 s: 41616% predicted)
were recruited. Tight glycaemic control was feasible
(78% CBG measurements and 89% of insulin-dose
adjustments were adherent to protocol) and acceptable
to patients. 0.2% CBG measurements were
<2.2 mmol/l and 4.1% measurements 2.2e3.3 mmol/l.
The study CBG and proportion of measurements/time
in target range were similar to that of ICU studies,
whereas the fasting CBG was lower, and the glycaemic
variability was greater.
Conclusions: Tight glycaemic control is feasible and
has similar safety and efﬁcacy on AMU to ICU.
However, as more recent ICU studies have shown no
beneﬁt and possible harm from tight glycaemic
control, alternative strategies for blood glucose control
in COPD exacerbations should now be explored.
Trial registration number: ISRCTN: 42412334.
http://Clinical.Trials.gov NCT00764556.
INTRODUCTION
Half of all COPD patients admitted to
hospital with exacerbations have elevated
random blood glucose $7 mmol/l.
1 2 This
hyperglycaemia is caused not only by under-
lying glucose intolerance (5e18% have an
established diagnosis of diabetes mellitus) or
steroid use prior to hospital admission (18%
patients) but also by the physiological stress
of acute illness. Underlying mechanisms
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ARTICLE SUMMARY
Article focus
- Hyperglycaemia is associated with poor
outcomes from acute chronic obstructive pulmo-
nary disease (COPD) exacerbations requiring
hospital admission.
- It is not known whether glycaemic control can
improve COPD exacerbation outcomes.
- The aim of this phase II study was to determine
the feasibility, safety and efﬁcacy of tight
glycaemic control with insulin in COPD patients
with exacerbations on acute medical wards,
towards testing this intervention in a randomised
controlled trial.
Key messages
- Tight glycaemic control with insulin was feasible
and acceptable to patients in a general ward
setting.
- The efﬁcacy and safety of tight glycaemic control
were similar in COPD patients on acute medical
wards to that achieved in intensive care settings,
with improved glycaemic control but increased
hypoglycaemia and glycaemic variability.
Strengths and limitations of this study
- This study was conducted when tight glycaemic
control was standard practice in intensive care
units (ICUs), following the publication of two
single-centre studies demonstrating reduced
morbidity and mortality compared with conven-
tional glycaemic control.
- More recent ICU studies have shown no beneﬁt
and possible harm from tight glycaemic control.
- In this context, our ﬁnding that tight glycaemic
control in the acute medical unit has a similar
safety and efﬁcacy to ICU protocols indicates that
we should explore alternative strategies for blood
glucose control in COPD exacerbations.
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Open Access Researchinclude induction of peripheral insulin resistance by
hypoxia,
3 acidosis
4 and systemic inﬂammation.
5
Acute hyperglycaemia during COPD exacerbations is
associated with poor exacerbation outcomes. In a retro-
spective study, the risk of death or prolonged hospital
stay during COPD exacerbations was increased by 15%
for each 1 mmol/l increase in plasma glucose.
1 In
a prospective study of COPD patients with type II respi-
ratory failure requiring non-invasive ventilation (NIV),
acute hyperglycaemia, but not diabetes mellitus, was
associated with NIV failure.
2 In COPD patients on
respiratory intensive care units (ICUs), hyperglycaemia
was associated with ‘late failure’ (>48 h) of NIV after
initial success.
6
A causative link between hyperglycaemia and poor
outcomes from COPD exacerbations has not been
proven. However, hyperglycaemia could be detrimental
for COPD patients by driving infection, inﬂammation
and myopathy. In COPD patients with exacerbations,
acute hyperglycaemia is associated with increased likeli-
hood of positive sputum cultures
1 and increased risk of
hospital-acquired pulmonary infection.
6 Experimental
hyperglycaemia raises plasma levels of pro-inﬂammatory
cytokines, including IL-6, TNF-a and IL-18.
7 In mouse
models of hyperglycaemia, high glucose concentrations
stimulate muscle-protein degradation and inhibit
protein synthesis, which could contribute to muscle
wasting.
8
If hyperglycaemia is truly detrimental during COPD
exacerbations, then control of blood glucose could
improve exacerbation outcomes. However, there is
currently no evidence to inform practice in this
patient group. Intensive insulin therapy to control blood
glucose to physiological concentrations has been
tested on ICUs in critically ill patients with acute hyper-
glycaemia. In mechanistic studies, tight glycaemic
control with insulin reduced septicaemia and the
need for prolonged antibiotic therapy,
9 prevented
nosocomial infection,
10 accelerated resolution of
inﬂammation
11 and reduced muscle catabolism.
12 13
Despite these physiological beneﬁts, a meta-analysis of
26 studies found no difference in mortality between
patients undergoing tight glycaemic control and
those receiving usual care.
14 This may be explained by
a sixfold increase in the rate of hypoglycaemia in
patients undergoing intensive insulin therapy, which
may have negated the beneﬁcial effects of blood glucose
control.
COPD patients requiring hospital admission for exac-
erbations are usually managed on general wards outside
ICU. In this environment, blood glucose control is poor
even in patients with an established diagnosis of diabetes
mellitus.
15 There are no randomised controlled trials to
inform management of acute hyperglycaemia in patients
without prior diabetes mellitus in this setting, and
current best practice is based on clinical experience
and judgement.
16 Barriers to effective glycaemic control
include fear of hypoglycaemia, inappropriate use of
medication and lack of knowledge and training.
17 The
aim of our study was to develop a protocol for control of
acute hyperglycaemia in COPD patients with exacerba-
tions managed on acute medical wards and to determine
the feasibility, safety and efﬁcacy of this protocol.
METHODS
Study design
A prospective, non-randomised, phase II, single-arm
study of tight glycaemic control was conducted in
patients with acute exacerbations of COPD admitted to
the acute medical unit (AMU) of St George’s Hospital.
The AMU consists of 60 beds on two sites and has
a nurse:patient care ratio of 1:6. The study was
conducted in accordance with the Declaration of
Helsinki and was approved by the Medicines and
Healthcare Regulatory Authority (UK) and National
Research Ethics Committee. All participants gave
written, informed consent for inclusion in the study.
Participants
Patients admitted to AMU with an acute exacerbation of
COPD within the previous 48 h who gave written
informed consent were entered into the study. COPD
exacerbations were deﬁned as acute deterioration in
symptoms from baseline including one or more of:
increased cough, wheeze, dyspnoea or sputum volume;
change in sputum colour; or chest tightness. Exclusion
criteria were: predicted short admission (<48 h); ICU
admission; moribund or not for active treatment; type 1
diabetes mellitus; increased risk of hypoglycaemia (eg,
renal or hepatic failure); reduced awareness of potential
hypoglycaemia (low Glasgow coma score or treatment
with b-blockers).
Assessment at study entry
Demographic information collected on all participants
included age and gender.
Chronic obstructive pulmonary disease
Smoking history, prior diagnosis of COPD by respiratory
specialist or spirometry, exacerbation symptoms, admis-
sion chest x-ray results, arterial blood gases, inﬂamma-
tory markers (C reactive protein (CRP) and white cell
count (WCC)) and discharge spirometry were recorded.
Use of oral corticosteroids before or during hospital
admission was noted.
Glucose tolerance
Body mass index, prior diagnosis of type 2 diabetes,
HbA1C and capillary blood glucose (CBG) were recorded
at study entry.
Clinical care during COPD exacerbations
Participants received care for their COPD exacerbations
at the discretion of the treating clinician according to
local guidelines. In patients with type 2 diabetes mellitus,
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entry and recommenced prior to hospital discharge.
Protocol for glycaemic control
The aim of the protocol was to control CBG to
4.4e6.5 mmol/l using insulin as required.
Choice of blood glucose target
The majority of ICU studies of intensive insulin therapy
have aimed to control blood glucose to physiological
concentrations (#6.1 mmol/l).
14 We selected a slightly
higher blood glucose target of 4.4e6.5 mmol/l because
of the unknown risk of hypoglycaemia in non-diabetic
COPD patients with acute, but not critical, illness on
general medical wards.
CBG measurements
Blood was obtained by ﬁngerprick and analysed using
a bedside glucometer (OneTouch Ultra2, LifeScan,
High Wycombe, UK). The same device was used for all
measurements in the study and was calibrated weekly.
CBG monitoring and insulin administration
Participants commenced three-hourly monitoring of
CBG. When CBG was >6.5 mmol/l, an intravenous
insulin infusion was started (50 IU soluble insulin in
50 ml NaCl 0.9%) at a predeﬁned rate according to
protocol. The insulin infusion rate was adjusted in
response to hourly CBG measurements.
After at least 24 h of intravenous insulin, daytime
(07:00e23:00) and night-time (23:00e07:00) insulin
requirements were calculated and converted to a subcu-
taneous basal-bolus insulin regime. Basal insulin was
given as once-daily insulin glargine or twice-daily insulin
detemir. Insulin aspart was given three times daily with
meals. CBG was monitored every 3 h, and insulin dose
was adjusted daily to maintain blood glucose at
4.4e6.5 mmol/l. Subcutaneous insulin was continued
until discharge or until respiratory function had
returned to premorbid levels.
Hypoglycaemia
Hypoglycaemia was deﬁned as CBG #3.3 mmol/l or
as symptoms consistent with hypoglycaemia with CBG
3.4e6.6 mmol/l. On detection of hypoglycaemia,
participants were immediately given oral or intravenous
glucose. CBG was remeasured and glucose administered
every 20 min until CBG >3.3 mmol/l and/ or until
symptoms had resolved. Intravenous insulin infusions
were stopped immediately on detection of hypo-
glycaemia and restarted at half the previous infusion rate
once the CBG was >6.5 mmol/l. During subcutaneous
insulin treatment, CBG monitoring was continued
hourly after hypoglycaemia until the next meal when
insulin doses were reviewed.
Serum potassium
If serum potassium (K
+) concentrations were
<3.5 mmol/l at study entry, participants received oral or
intravenous replacement to ensure a K
+ concentration of
$3.5 mmol/l prior to insulin administration. When
insulin treatment was started, K
+ was checked at 2, 4 and
6 h, then six-hourly during intravenous insulin and
24-hourly during subcutaneous insulin treatment. A K
+
of <3.5 mmol/l during insulin treatment was treated
with potassium replacement.
Outcome measures and analysis
Safety
The primary outcome measure for the study was the
frequency of severe hypoglycaemia, deﬁned as neuro-
glycopaenic symptoms (agitation (other than mild),
drowsiness, confusion, ataxia) responsive to administra-
tion of carbohydrate. Secondary safety outcome measures
were: frequency of symptomatic hypoglycaemia (CBG
#3.3 mmol/l OR <2.2 mmol/l with autonomic symp-
toms (sweating, tremor, palpitations, tachycardia));
frequency of asymptomatic hypoglycaemia (CBG
#3.3 mmol/l OR <2.2 mmol/l without symptoms);
and frequency of hypokalaemia (serum potassium
<3.5 mmol/l).
Efﬁcacy
Efﬁcacy of glycaemic control was assessed by: fasting
morning CBG (median of all 06:00 CBG values); study
CBG concentration (median of all CBG values);
proportion of all CBG measurements/time spent in
target range (4.4e6.5 mmol/l); hyperglycaemic index
(median area under the curve of blood glucose over
time above the hyperglycaemic threshold (6.5 mmol/l)
calculated by the trapezoidal rule)
18; and blood glucose
variability (6SD from mean blood glucose).
Protocol adherence
CBG measurements were deﬁned as adherent to
protocol if taken within 610 min of the time stated by
the protocol. Treatment decisions were deﬁned as
adherent to protocol if an appropriate adjustment or
non-adjustment of insulin treatment was made in
response to CBG level. This was only assessed during
intravenous insulin administration.
Patient acceptability
Patient acceptance of insulin treatment and CBG moni-
toring was assessed using a Likert Scale questionnaire.
Comparison to outcomes of ICU studies
Studies were identiﬁed from a systematic review of tight
glycaemic control in critically ill patients on ICU.
19
Original papers were obtained and searched to identify
the target blood-glucose range and indicators of safety,
efﬁcacy and protocol adherence. For each indicator,
mean or median values from individual studies were
included in the analysis, and median, minimum and
maximum values for all studies were calculated.
Statistics
Values with normal distribution are presented as
mean6SD and compared using unpaired or paired
t tests. Values that are not normally distributed are
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ManneWhitney U or Wilcoxon signed rank tests. Cate-
gorial variables are expressed as percentages and
compared using c
2 tests. A statistical analysis was carried
out using SPSS for Windows, V.16.0. A p value of <0.05
was considered signiﬁcant.
RESULTS
Study entry
Twenty participants (10 females, age 7169 years) were
enrolled in the study.
Lung function
Participants had a 65643 pack-year smoking history. All
had a formal diagnosis of COPD and discharge spirom-
etry was forced expiratory volume in 1 s (FEV1)4 1 616%
predicted, FEV1/forced vital capacity% 53618% (n¼18).
Exacerbations were characterised by increased dyspnoea
(100%), wheeze (85%), chest tightness (70%) and
cough (65%). Chest x-ray showed consolidation in 15%
patients, and 20% patients had type II respiratory failure
(pH 7.2360.15, Paco2 10.865.1 kPa). CRP was 21
(7e70) mg/l, and WCC was 12.767.3310
9/l. Fifty per
cent of participants were taking oral corticosteroids prior
to hospital admission, and all patients received prednis-
olone 30 mg daily during the inpatient stay.
Glucose tolerance
Men weighed 89624 kg, with a body mass index (BMI) of
31.569.1 kg/m
2, and women weighed 55613 kg, with
a BMI of 22.465.9 kg/m
2. HbA1C was 6.260.5% in
participants without prior diabetes (n¼16) and 7.961.6%
in participants with diabetes (n¼4). Diabetes was treated
with diet (n¼2) or oral hypoglycaemics (n¼2).
Insulin treatment
Twenty participants received insulin for a total of
90 days. Insulin was commenced when CBG was
>6.5 mmol/l, either at (n¼17) or within 3 h (n¼3) of
study entry. Participants received intravenous insulin for
28 (26e41) h at 55 (33e101) IU/24 h, and then subcu-
taneous insulin for 88 (48e123) h at 46 (20e74) IU/
24 h. Insulin requirements by gender and for patients
with and without diabetes mellitus are shown in table 1.
Male patients with and without diabetes received similar
amounts of insulin, although blood glucose was less well
controlled in the patients with diabetes. Outcome
measures during intravenous and subcutaneous insulin
treatment are compared in table 2.
Insulin requirements in the ﬁrst 24 h were signiﬁcantly
correlated with WCC (R¼0.692, p¼0.001), HbA1c
(R¼0.593, p¼0.006) and body weight (R¼0.820,
p¼0.000), but not with age, lung function, CRP, arterial
pH or Paco2. Insulin requirements were not affected by
oral corticosteroid use prior to hospital admission. On
univariate analysis, weight was the only independent
predictor of insulin requirement in the ﬁrst 24 h.
Outcomes
Outcome measures for the whole group are summarised
and compared with outcomes of ICU studies in table 3.
Twenty-ﬁve ICU studies with a blood glucose target range
of 4.560.6 to 6.860.8 mmol/l were included in the
analysis.
Safety
Participants had 1111 CBG measurements in total.
There was a single episode of severe hypoglycaemia with
confusion and CBG 2.3 mmol/l. This was caused by
Table 1 Comparison of treatment and outcomes in participants with and without type 2 diabetes mellitus
No diabetes (n[16) Type 2 diabetes (n[4) p Value
Study entry
Entry CBG (mmol/l) 8.7 (6.5e12.1) 11.9 (8.7e17.7) 0.211
Weight (kg) 6 male: 86625 4 male: 93626 0.762
10 female: 55613 ee
BMI (kg/m
2) 6 male: 31.1610 4 male: 32.069.3 1.0
10 female: 22.465.9 ee
Treatment
Intravenous insulin (IU/24 h) 6 male: 74 (43e93) 4 male: 116 (57e146) 0.257
10 female: 36 (20e66) e
Subcutaneous insulin (IU/24 h) 5 male: 67 (34e81) 4 male: 90 (26e118) 0.571
7 female: 20 (16e53) e
Safety
CBG <2.2 mmol/l (% measurements) 0.2% 0% 0.674
CBG #3.3 mmol/l (%) 4.5% 2.0% 0.071
Efﬁcacy
Study CBG (mmol/l) 5.8 (5.3e6.3) 6.9 (6.2e8.0) 0.022
06:00 CBG (mmol/l) 4.7 (4.2e5.2) 6.1 (5.8e6.2) 0.004
Percentage of CBG measurements in target range 43 27 0.000
Percentage of time CBG in target range 44612 2869 0.024
Hyperglycaemic index 1.0 (0.6e1.2) 1.7 (1.6e2.2) 0.005
Glycaemic variability (mmol/l) 2.760.7 3.160.7 0.395
CBG, capillary blood glucose.
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insulin was administered 2.5 h after eating rather than
before the meal.
There were three episodes of symptomatic hypo-
glycaemia with blurred vision and sweating, CBG 2.8
(2.6e2.9) mmol/l. There were 41 episodes of asymp-
tomatic hypoglycaemia, 39 with CBG 2.2e3.3 mmol/l
(2.9 (2.6e3.2) mmol/l) and two with CBG <2.2 mmol/l
(1.1 and 1.9 mmol/l). The percentage of CBG
measurements <2.2 mmol/l was within the range seen
in ICU studies, although CBG#3.3 mmol/l occurred
more frequently in AMU (table 3).
Two (10%) patients each had one episode where
CBG was <2.2 mM. In single-centre
20 and multicentre
21
intensive insulin trials, 18.7% and 6.8% patients respec-
tively on intensive insulin therapy experienced severe
hypoglycaemia.
All hypoglycaemic events were treated promptly with
oral glucose, and the time from detection of hypo-
glycaemia to CBG >3.3 mmol/l was 35 (25e60) min.
There was no evidence of clinical complications
following hypoglycaemia.
Serum potassium was 4.260.4 mmol/l at study entry
and fell by 0.660.3 mmol/l (p¼0.000) during insulin
treatment. Serum potassium fell below 3.5 mmol/l
(3.0e3.4 mmol/l) in ﬁve patients and was corrected
promptly to >3.5 mmol/l with oral or intravenous
supplementation without clinical sequelae.
Table 2 Comparison of outcomes on intravenous and subcutaneous insulin
Intravenous insulin Subcutaneous insulin p Value
Dose in ﬁrst 24 h of insulin treatment (IU) 54 (36e81) 34 (17e70) 0.001
Median dose of insulin (IU/24 h) 55 (33e101) 46 (20e74) 0.017
Safety
Total no of CBG measurements 617 494
CBG <2.2 mmol/l (percentage of measurements) 0.2 0.2 0.844
CBG #3.3 mmol/l (percentage of measurements) 5 3 0.001
Efﬁcacy
Study CBG (mmol/l) 6.0 (5.2e6.3) 6.4 (5.7e6.9) 0.044
06:00 CBG (mmol/l) 4.8 (4.3e5.8) 5.2 (4.5e6.2) 0.127
Percentage of CBG measurements in target range 41 39 0.480
Percentage of time CBG in target range 40614 39614 0.511
Hyperglycaemic index 0.9 (0.6e1.6) 1.0 (0.7e1.7) 0.836
Glycaemic variability (mmol/l) 2.4 (2.0e3.4) 2.8 (2.5e3.4) 0.301
CBG, capillary blood glucose.
Table 3 Glycaemic indicators in studies of tight glycaemic control comparing outcomes on general medical wards (this study)
with published studies performed in intensive care units
19
Chronic obstructive
pulmonary disease patients
on general medical wards
Published intensive
care unit studies
No of intensive
care unit studies
using indicator
Safety
Capillary glucose <2.2 mmol/l
(percentage of measurements)
0.2 0.1 (range 0e0.2) 12
Capillary glucose #3.3 mmol/l
(percentage of measurements)
4.1 0.3 (range 0.1e2.1) 7
Efﬁcacy
Study CBG (mmol/l) 5.9 (IQR 5.4e6.5) 6.8 (range 5.7e8.5) 10
06:00 CBG (mmol/l) 4.8 (IQR 4.4e5.8) 6.5 (range 5.7e8.1) 5
Percentage of CBG measurements
in target range
40 51 (range 29e69) 11
Percentage of time CBG in target range 41 53 (range 34e96) 9
Hyperglycaemic index 1.1 (IQR 0.7e1.6)
(threshold 6.5 mmol/l)
1.0 (IQR 0.9e1.8)
(threshold 6.0 mmol/l)
2
Glycaemic variability (mmol/l) 2.9 (IQR 2.2e3.3) 1.7 (IQR 1.3e2.3) 4
Protocol adherence
Adherent CBG measurements (%) 82 53 (range 29e98) 4
Adherent insulin (intravenous) dose
adjustments (%)
89 72 (range 56e100) 4
Values are median values for participants (this study) or for studies (ICU).
19 The range is minimumdmaximum.
CBG, capillary blood glucose.
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CBG was 9.7 (7.6e12.2) mmol/l at study entry, and all
participants required insulin during the study. Study
CBG concentrations, proportion of all CBG measure-
ments/time spent in target range and hyperglycaemic
index were within the ranges achieved by ICU studies
(table 3). Fasting morning CBG values appeared lower
than those seen in ICU studies, and CBG was more likely
to be in the target range during the night (23:00e07:00,
58%) than during the day (7:00e23:00, 32%, p¼0.001).
Glycaemic variability was greater in COPD patients than
on ICU. Glycaemic control was worse in participants with
type 2 diabetes compared with non-diabetic patients
(table 1).
Protocol adherence
Overall protocol adherence was at least as good as that
seen in ICU studies (table 3). Of 1111 CBG measure-
ments, 82% were adherent to protocol, 8% were early,
and 10% were late. Of the late measurements, four
(0.3% of all measurements) were #3.4 mmol/l and may
have delayed identiﬁcation of hypoglycaemia.
During intravenous insulin administration, 89% of
treatment decisions were adherent to protocol. The non-
adherent decisions resulted in: inappropriate cessation
of insulin treatment (34%), inadequate insulin (7%),
failure to change insulin appropriately (35%) and too
much insulin (24%). One decision to give too much
insulin was followed by asymptomatic hypoglycaemia.
Patient acceptability
Fourteen participants completed the questionnaire. In
general, the study was well tolerated with 12 patients
being willing to go through the same procedures again.
Seven participants expressed concerns about risk of
hypoglycaemia, two were unhappy with the number of
ﬁngerpricks required to measure CBG, and seven found
that the study interrupted their sleep.
DISCUSSION
We used an intensive insulin protocol to control acute
hyperglycaemia in patients admitted to an acute medical
unit with exacerbations of COPD. Tight glycaemic
control was acceptable to patients in this healthcare
setting and was feasible, with 82% of CBG (CBG)
measurements and 89% of insulin dose adjustment
decisions being adherent to protocol. From a safety
perspective, severe hypoglycaemia (CBG <2.2 mmol/l)
was rare, but moderate hypoglycaemia (CBG 2.2e
3.3 mmol/l) was more common. Median study and
fasting morning CBG values and 40% of all measure-
ments were in the target range of 4.4e6.5 mmol/l. Tight
glycaemic control was therefore feasible in the acute
medical unit and could be performed with similar safety
and efﬁcacy to tight glycaemic control in ICU (table 3).
Intensive insulin treatment to control acute hyper-
glycaemia has been extensively evaluated for patients
with critical illness on ICU. Even in this setting, with
a high nursing:patient ratio, intensive monitoring,
controlled nutrition and lack of patient activity, blood
glucose control is imperfect, achieving 29e69% blood
glucose measurements within the target range (table 3).
Prior to this study, we did not know whether control of
acute hyperglycaemia to a target blood glucose range
could be achieved in the acute medical unit (AMU),
where lower nurse:patient ratios, less intensive moni-
toring and erratic nutrition and activity present barriers
to glycaemic control. Despite these impediments, we
found that tight glycaemic control with insulin was
feasible in the AMU. Part of this success was directly
attributable to care provided by a dedicated study
physician. However, the majority of CBG measurements
and insulin adjustments were made by clinical nurses
supported by a written protocol and telephone advice.
Other studies have found that computerised decision
support further improved glycaemic control.
22
A key aim of our study was to determine the safety of
tight glycaemic control on the acute medical unit.
Hypoglycaemia is the most important adverse reaction in
patients treated with insulin. In critically ill patients
undergoing tight glycaemic control on ICU, hypo-
glycaemia was independently associated with mortality,
23
and the adverse effects of hypoglycaemia potentially
offset the beneﬁcial effects of insulin. Hypoglycaemia
with CBG <2.2 mmol/l occurred with a similar
frequency in our study to that seen in ICU studies
(table 3). CBG measurements have been shown to be
inaccurate in detecting hypoglycaemia in critically ill
patients.
24 It is therefore possible that our study under-
estimated the frequency of hypoglycaemia. There were
no obvious immediate detrimental consequences of
hypoglycaemia in participants in our study, but it was not
designed to detect these. Patients on general wards may
be less susceptible to immediate adverse effects of severe
hypoglycaemia than ICU patients owing to less serious
illness or more effective counter-regulatory responses.
They should also potentially be able to report symptoms
of low blood glucose early to prevent severe hypo-
glycaemia. However, in our study, the majority of hypo-
glycaemic episodes were asymptomatic, probably
because hypoglycaemia was detected biochemically at
concentrations above those at which autonomic activa-
tion and neuroglycopaenic symptoms occur.
25 Hypo-
glycaemia could also have long-term detrimental effects
on cognitive function, although detection of this was
beyond the scope of our study. In older patients with
type 2 diabetes (mean 65 years), the risk of dementia was
increased by 2.4% per year by occurrence of severe
hypoglycaemia.
26
An increase in glycaemic variability (excursions of
blood glucose around the mean) may also be an adverse
effect of tight glycaemic control with detrimental
consequences. In ICU patients, increased glycaemic
variability was associated with increased risk of
death.
27 Glycaemic variability activates oxidative stress,
28
impairs endothelial-mediated vascular relaxation
29 and
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inﬂammatory cytokines.
7 Patients in our study had
considerable glycaemic variability, which was greater
than that seen in ICU studies. Glycaemic variability was
probably increased by insulin treatment, although we did
not have an untreated comparator group to conﬁrm this.
Blood-glucose control in COPD patients with exacer-
bations may provide some insights into mechanisms
underlying acute hyperglycaemia. Weight was the only
independent predictor of insulin requirements, indi-
cating increased insulin resistance in heavier patients
consistent with other patient groups.
30 However, as most
patients had a normal HbA1c, indicating normal glucose
tolerance prior to hospital admission, and all patients
required insulin even if underweight, chronic insulin
resistance is not the only responsible mechanism. In
COPD patients, blood-glucose control was better at night
than in the morning, and fasting morning blood glucose
was well below the range seen in ICU patients (table 3).
This could be explained by nutritional intake during the
day, but also could be an effect of oral corticosteroids.
After a dose of oral prednisolone 30 mg, blood-glucose
concentrations rise to a maximum concentration at
around 9 h postdose.
31 Study participants were prescribed
prednisolone at 08:00 with a predicted maximal
glycaemic effect at 17:00. In this small study in patients
with a similar severity of acute illness, all of whom were
taking a large dose of oral corticosteroids, it was not
possible to detect an effect of illness severity on insulin
resistance. In an ICU study, development of pneumonia
in patients with severe injury was associated with
increased insulin requirements.
32
We have shown that tight glycaemic control can be
achieved on the acute medical unit with a similar safety
and efﬁcacy to that accomplished in intensive care.
However, the major limitation of our study is that it is still
not known whether and to what levels blood glucose
should be controlled in this acute situation. In the
absence of prospective, randomised controlled trials,
current recommendations for management of acute
hyperglycaemia outside the ICU setting are based on
clinical experience and judgement.
16 A consensus
statement on inpatient glycaemic control from the
American Association of Clinical Endocrinologists and
American Diabetes Association identiﬁed ‘investigation
of optimal and safe glycaemic targets in non-critically ill
patients on medical and surgical wards’ as an important
area for future research.
16
In summary, hyperglycaemia is associated with adverse
outcomes from COPD exacerbations, and control of
blood glucose could potentially improve management of
infection, inﬂammation and myopathy that underlie
exacerbations. Blood glucose can be controlled with
insulin to a predeﬁned target in patients on an acute
medical unit with similar safety and efﬁcacy to that
achieved in ICU. However, this study was conducted
when tight glycaemic control was standard practice in
intensive care units (ICU), following the publication
of two single-centre studies demonstrating reduced
morbidity and mortality compared with conventional
glycaemic control. More recent ICU studies have shown
no beneﬁt and possible harm from tight glycaemic
control. In this context, our ﬁnding that tight glycaemic
control in the acute medical unit has a similar safety and
efﬁcacy to ICU protocols indicates that we should
explore alternative strategies for blood-glucose control
in COPD exacerbations.
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